EVOLUS, INC. Selling, General and Administrative Expense
EVOLUS, INC. (EOLS) reported Selling, General and Administrative Expense of $57.05 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- EVOLUS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $57.05M, a 0.67% increase year-over-year.
- EVOLUS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $51.98M, a 8.23% decline year-over-year.
- EVOLUS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $54.66M, a 8.78% increase year-over-year.
- EVOLUS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $52.82M, a 0.59% increase year-over-year.
- EVOLUS, INC. selling, general and administrative expense for fiscal 2025 was $220.79M, a 11.49% increase from fiscal 2024.
- EVOLUS, INC. selling, general and administrative expense for fiscal 2024 was $198.03M, a 20.06% increase from fiscal 2023.
- EVOLUS, INC. selling, general and administrative expense for fiscal 2023 was $164.94M, a 16.29% increase from fiscal 2022.
- EVOLUS, INC. selling, general and administrative expense for fiscal 2022 was $141.84M, a 26.57% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 3 month as first filed | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 6 month as first filed | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $57.05M 10-Q · filed 2026-08-05 | $109.03M 10-Q · filed 2026-08-05 | $163.69M derived: sum of 3 quarters · filed 2026-08-05 | $216.50M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | $51.98M 10-Q · filed 2026-05-04 | $106.64M derived: sum of 2 quarters · filed 2026-05-04 | $159.45M derived: sum of 3 quarters · filed 2026-05-04 | $216.13M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $54.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $107.47M derived: sum of 2 quarters · filed 2026-03-03 | $164.15M derived: sum of 3 quarters · filed 2026-08-05 | $220.79M 10-K · filed 2026-03-03 | |||
| 2025-09-30 | $52.82M 10-Q · filed 2025-11-05 | $109.49M derived: sum of 2 quarters · filed 2026-08-05 | $166.13M 10-Q · filed 2025-11-05 | $216.38M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $56.67M 10-Q · filed 2026-08-05 | $113.31M 10-Q · filed 2026-08-05 | $163.56M derived: sum of 3 quarters · filed 2026-08-05 | $216.06M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $56.64M 10-Q · filed 2026-05-04 | $106.88M derived: sum of 2 quarters · filed 2026-05-04 | $159.39M derived: sum of 3 quarters · filed 2026-05-04 | $209.54M derived: sum of 4 quarters · filed 2026-05-04 | |||
| 2024-12-31 | $50.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $102.75M derived: sum of 2 quarters · filed 2026-03-03 | $152.90M derived: sum of 3 quarters · filed 2026-03-03 | $198.03M 10-K · filed 2026-03-03 | |||
| 2024-09-30 | $52.51M 10-Q · filed 2025-11-05 | $102.66M derived: sum of 2 quarters · filed 2025-11-05 | $147.78M 10-Q · filed 2025-11-05 | $190.84M derived: sum of 4 quarters · filed 2026-03-03 | |||
| 2024-06-30 | $50.15M 10-Q · filed 2025-08-05 | $95.28M 10-Q · filed 2025-08-05 | $138.33M derived: sum of 3 quarters · filed 2026-03-03 | $181.66M derived: sum of 4 quarters · filed 2026-03-03 | |||
| 2024-03-31 | $45.12M 10-Q · filed 2025-05-07 | $88.18M derived: sum of 2 quarters · filed 2026-03-03 | $131.51M derived: sum of 3 quarters · filed 2026-03-03 | $172.68M derived: sum of 4 quarters · filed 2026-03-03 | |||
| 2023-12-31 | $43.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $86.39M derived: sum of 2 quarters · filed 2026-03-03 | $127.56M derived: sum of 3 quarters · filed 2026-03-03 | $164.94M 10-K · filed 2026-03-03 | |||
| 2023-09-30 | $43.33M 10-Q · filed 2024-11-06 | $84.50M derived: sum of 2 quarters · filed 2024-11-06 | $121.89M 10-Q · filed 2024-11-06 | $158.62M derived: sum of 4 quarters · filed 2025-03-04 | |||
| 2023-06-30 | $41.17M 10-Q · filed 2024-07-31 | $78.56M 10-Q · filed 2024-07-31 | $115.29M derived: sum of 3 quarters · filed 2025-03-04 | $150.08M derived: sum of 4 quarters · filed 2025-03-04 | |||
| 2023-03-31 | $37.38M 10-Q · filed 2024-05-07 | $74.11M derived: sum of 2 quarters · filed 2025-03-04 | $108.91M derived: sum of 3 quarters · filed 2025-03-04 | $145.78M derived: sum of 4 quarters · filed 2025-03-04 | |||
| 2022-12-31 | $36.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $71.52M derived: sum of 2 quarters · filed 2025-03-04 | $108.40M derived: sum of 3 quarters · filed 2025-03-04 | $141.84M 10-K · filed 2025-03-04 | |||
| 2022-09-30 | $34.79M 10-Q · filed 2023-11-07 | $71.67M derived: sum of 2 quarters · filed 2023-11-07 | $105.11M 10-Q · filed 2023-11-07 | $138.38M derived: sum of 4 quarters · filed 2023-11-07 | |||
| 2022-06-30 | $36.88M 10-Q · filed 2023-08-02 | $70.32M 10-Q · filed 2023-08-02 | $103.58M derived: sum of 3 quarters · filed 2023-08-02 | $135.26M derived: sum of 4 quarters · filed 2023-08-02 | |||
| 2022-03-31 | $33.44M 10-Q · filed 2023-05-09 | $66.71M derived: sum of 2 quarters · filed 2023-05-09 | $98.38M derived: sum of 3 quarters · filed 2023-05-09 | $124.84M derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | $33.27M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $64.94M derived: sum of 2 quarters · filed 2023-03-08 | $91.40M derived: sum of 3 quarters · filed 2023-03-08 | $112.07M 10-K · filed 2023-03-08 | |||
| 2021-09-30 | $31.67M 10-Q · filed 2022-11-08 | $31.68M 10-Q · filed 2021-11-02 | $58.14M derived: sum of 2 quarters · filed 2022-11-08 | $78.80M 10-Q · filed 2022-11-08 | $78.83M 10-Q · filed 2021-11-02 | $106.19M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | $26.46M 10-Q · filed 2022-08-02 | $26.47M 10-Q · filed 2021-08-04 | $47.13M 10-Q · filed 2022-08-02 | $47.15M 10-Q · filed 2021-08-04 | $74.52M derived: sum of 3 quarters · filed 2022-08-02 | $96.47M derived: sum of 4 quarters · filed 2022-08-02 | |
| 2021-03-31 | $20.66M 10-Q · filed 2022-05-10 | $20.68M 10-Q · filed 2021-05-12 | $48.06M derived: sum of 2 quarters · filed 2022-05-10 | $70.00M derived: sum of 3 quarters · filed 2022-05-10 | $87.56M derived: sum of 4 quarters · filed 2022-05-10 | ||
| 2020-12-31 | $27.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $49.34M derived: sum of 2 quarters · filed 2022-03-03 | $66.89M derived: sum of 3 quarters · filed 2022-03-03 | $98.19M 10-K · filed 2022-03-03 | |||
| 2020-09-30 | $21.94M 10-Q · filed 2021-11-02 | $39.50M derived: sum of 2 quarters · filed 2021-11-02 | $70.80M 10-Q · filed 2021-11-02 | $101.08M derived: sum of 4 quarters · filed 2021-11-02 | |||
| 2020-06-30 | $17.55M 10-Q · filed 2021-08-04 | $48.85M 10-Q · filed 2021-08-04 | $79.14M derived: sum of 3 quarters · filed 2021-08-04 | $110.03M derived: sum of 4 quarters · filed 2021-08-04 | |||
| 2020-03-31 | $31.30M 10-Q · filed 2021-05-12 | $61.59M derived: sum of 2 quarters · filed 2021-05-12 | $92.48M derived: sum of 3 quarters · filed 2021-05-12 | $127.37M derived: sum of 4 quarters · filed 2021-05-12 | |||
| 2019-12-31 | $30.29M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $61.18M derived: sum of 2 quarters · filed 2021-03-25 | $96.07M derived: sum of 3 quarters · filed 2021-03-25 | $113.59M 10-K · filed 2021-03-25 | |||
| 2019-09-30 | $30.90M 10-Q · filed 2020-10-29 | $65.79M derived: sum of 2 quarters · filed 2020-10-29 | $83.31M 10-Q · filed 2020-10-29 | $95.53M derived: sum of 4 quarters · filed 2020-10-29 | |||
| 2019-06-30 | $34.89M 10-Q · filed 2020-08-10 | $52.41M 10-Q · filed 2020-08-10 | $64.63M derived: sum of 3 quarters · filed 2020-08-10 | $71.84M derived: sum of 4 quarters · filed 2020-08-10 | |||
| 2019-03-31 | $17.52M 10-Q · filed 2020-05-11 | $29.74M derived: sum of 2 quarters · filed 2020-05-11 | $36.95M derived: sum of 3 quarters · filed 2020-05-11 | $43.20M derived: sum of 4 quarters · filed 2020-05-11 | |||
| 2018-12-31 | $12.22M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $19.43M derived: sum of 2 quarters · filed 2020-02-25 | $25.68M derived: sum of 3 quarters · filed 2020-02-25 | $29.15M 10-K · filed 2020-02-25 | |||
| 2018-09-30 | $7.21M 10-Q · filed 2019-11-04 | $13.46M derived: sum of 2 quarters · filed 2019-11-04 | $16.92M 10-Q · filed 2019-11-04 | ||||
| 2018-06-30 | $6.25M 10-Q · filed 2019-08-12 | $9.71M 10-Q · filed 2019-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |